Clinical

Dataset Information

0

A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients


ABSTRACT: The purpose of this study is to determine in a randomized, placebo-controlled, phase II trial if the combination of sulindac and erlotinib causes a significant regression of duodenal and colorectal adenomas in familial adenomatous polyposis (FAP) and attenuated FAP (AFAP) patients.

DISEASE(S): Adenomatous Polyposis Coli,Colorectal Neoplasms,Nasopharyngeal Neoplasms

PROVIDER: 2094034 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2018-02-16 | GSE94919 | GEO
2023-08-07 | GSE189035 | GEO
| 2116545 | ecrin-mdr-crc
2018-02-27 | GSE111156 | GEO
| 2206253 | ecrin-mdr-crc
| 2332203 | ecrin-mdr-crc
| PRJNA436023 | ENA
| 2065289 | ecrin-mdr-crc
| 2074251 | ecrin-mdr-crc
| 2098444 | ecrin-mdr-crc